BNTX — BioNTech SE Cashflow Statement
0.000.00%
Last trade - 00:00- $24.48bn
- $5.70bn
- €2.75bn
- 83
- 32
- 90
- 77
Annual cashflow statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -146 | 15,046 | 12,954 | 1,186 | -678 |
| Depreciation | |||||
| Non-Cash Items | 188 | -32.6 | 248 | -577 | -551 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -94.9 | -14,199 | 252 | 4,579 | 1,138 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -13.5 | 890 | 13,577 | 5,371 | 208 |
| Capital Expenditures | -85.4 | -154 | -363 | -706 | -452 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -59.4 | -412 | 328 | -6,249 | -1,629 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -145 | -566 | -35.3 | -6,955 | -2,081 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 895 | 94.2 | -1,419 | -779 | -45.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 691 | 483 | 12,182 | -2,211 | -1,902 |